Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation
Open accessAbstract
OBJECTIVE: To examine the impact of schizophrenia, its treatment and treatment-related adverse events related to antipsychotics, on quality of life from the perspective of schizophrenia patients and laypersons. METHODS: Health state descriptions for stable schizophrenia, extra pyramidal symptoms (EPS), hyperprolactinemia, diabetes, weight gain and relapse were developed based on a review of the literature and expert opinion. The quality of life impact of each health state was elicited using a time trade-off instrument administered by interview to 49 stable schizophrenia patients and 75 laypersons. Regression techniques were employed to examine the importance of subject characteristics on health-related utility scores. RESULTS: Patients and laypersons completed the interview in similar times. Stable schizophrenia had the highest mean utility (0.87 and 0.92 for laypersons and patients respectively), while relapse (0.48 and 0.60) had the lowest mean utility. Of the treatment-related adverse events, EPS had the lowest mean utility (0.57 and 0.72, respectively). Age, gender and PANSS score did not influence the utility results independently of health state. On average, patient utilities are 0.077 points higher than utilities derived from laypersons, although the ranking was similar between the two groups. CONCLUSION: Events associated with schizophrenia and treatment of schizophrenia can bring about a significant detriment in patient quality of life, with relapse having the largest negative impact. Results indicate that patients with stable schizophrenia are less willing to trade years of life to avoid schizophrenia-related symptoms compared to laypersons. Both sets of respondents showed equal ability to complete the questionnaire.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An RCT of an adapted DPP for people with severe mental illness found significant reductions in obesity and other metabolic risk markers linked to antipsychotic treatment.
“an RCT of an adapted versions of the DPP for people with SMI observed significant reductions in obesity and other metabolic risk markers associated with antipsychotic treatment.240”
From The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness (2019) · cites this paper as [240]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736 · see citing works
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,703 · see citing works
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648 · see citing works
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544 · see citing works
Projection Bias in Predicting Future Utility
Loewenstein, G. F., O’Donoghue, T., & Rabin, M. (2003) · The Quarterly Journal of Economics · doi:10.1162/003355303322552784 · Cited by 1,079 · see citing works
Bellack, A. S. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj044 · Cited by 573 · see citing works
Visual Analog Scales: Do They Have a Role in the Measurement of Preferences for Health States?
Torrance, G. W., Feeny, D. H., & Furlong, W. J. (2001) · Medical Decision Making · doi:10.1177/0272989x0102100408 · Cited by 431 · see citing works
Ubel, P. A., Loewenstein, G. F., & Jepson, C. (2003) · Quality of Life Research · doi:10.1023/a:1025119931010 · Cited by 426 · see citing works
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R. (2002) · BMJ · doi:10.1136/bmj.325.7358.243 · Cited by 421 · see citing works
Robinson, R. (1993) · BMJ · doi:10.1136/bmj.307.6908.859 · Cited by 366 · see citing works
Visual Analog Scales: Do They Have a Role in the Measurement of Preferences for Health States?
Torrance, G. W., Feeny, D., & Furlong, W. (2001) · Medical Decision Making · doi:10.1177/02729890122062622 · Cited by 364
Räsänen, P., Roine, E., Sintonen, H., Semberg, V., Ryynänen, O., & Roine, R. P. (2006) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462306051051 · Cited by 285 · see citing works
Revicki, D. A., Shakespeare, A., & Kind, P. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606000-00004 · Cited by 98 · see citing works
Lysaker, P. H., Buck, K. D., Taylor, A. C., & Roe, D. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2007.04.023 · Cited by 82 · see citing works
Naturalistic Impact of Second-Generation Antipsychotics on Weight Gain
Brixner, D. I., Said, Q., Corey‐Lisle, P. K., Tuomari, A. V., L'Italien, G. J., Stockdale, W., & Oderda, G. M. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g564 · Cited by 46 · see citing works
Comparison of preferences for health outcomes in schizophrenia among stakeholder groups
Lee, T. T., Ziegler, J. K., Sommi, R. W., Sugar, C. A., Mahmoud, R. A., & Lenert, L. A. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00009-1 · Cited by 41 · see citing works
Assessing Health Utilities in Schizophrenia
Voruganti, L. N. P., Awad, A. G., Oyewumi, L. K., Cortese, L., Zirul, S., & Dhawan, R. (2000) · PharmacoEconomics · doi:10.2165/00019053-200017030-00005 · Cited by 39 · see citing works
Cost-utility analysis in schizophrenia.
Awad, A. G., & Voruganti, L. P. (1999) · PubMed · Cited by 25 · see citing works
Sevy, S. M., Nathanson, K. L., Schechter, C. B., & Fulop, G. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006903 · Cited by 20 · see citing works
Revicki, D. A., Shakespeare, A., & Kind, P. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199611020-00004 · Cited by 18 · see citing works
(2003) · Perfusion · doi:10.1191/0267659103pf639xx · Cited by 2 · see citing works
Adams, J., Davey, P., Jackson, D., Croker, V., Aristides, M., Mullen, K., & Montgomery, W. S. (2002) · Value in Health · doi:10.1016/s1098-3015(10)61085-6 · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Lee TT Ziegler JK Sommi R Sugar C Mahmoud R Lenert LA Comparison of preferences for health outcomes in schizophrenia among stakeholder groups Journal of Psychiatric Research 2000 34 201 210 10867115 10.1016/S0022-3956(00)00009-1 · DOI
- Sevy S Nathanson K Schlecter C Fulop G Contingency Valuation and Preferences of Health States Associated With Side Effects of Antipsychotic Medications in Schizophrenia Schizophrenia Bulletin 2001 27 643 651 11824490
Cited by
Sorted by citations
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531 · see citing works
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
Correll, C. U., Davis, R. E., Weingart, M., Saillard, J., O’Gorman, C., Kane, J. M., Lieberman, J. A., Tamminga, C. A., Mates, S. L., & Vanover, K. E. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4379 · Cited by 289 · see citing works
Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders
Saarni, S. I., Viertiö, S., Perälä, J., Koskinen, S., Lönnqvist, J., & Suvisaari, J. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.076489 · Cited by 251 · see citing works
Veronese, M., Santangelo, B., Jauhar, S., D’Ambrosio, E., Demjaha, A., Salimbeni, H., Jin, H., McCrone, P., Turkheimer, F., & Howes, O. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00866-7 · Cited by 58 · see citing works
Eiring, Ø., Landmark, B. F., Aas, E., Salkeld, G., Nylenna, M., & Nytrøen, K. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007848 · Cited by 57 · see citing works
Druais, S., Doutriaux, A., Cognet, M., Godet, A., Lançon, C., Lévy, P., Samalin, L., & Guillon, P. (2016) · PharmacoEconomics · doi:10.1007/s40273-015-0348-x · Cited by 51 · see citing works
Moncrieff, J., Lewis, G., Freemantle, N., Johnson, S., Barnes, T. R. E., Morant, N. J., Pinfold, V., Hunter, R. M., Kent, L., Smith, R., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030912 · Cited by 50 · see citing works
Fallon, P., Dursun, S., & Deakin, B. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311431105 · Cited by 47 · see citing works
Self-citationHatswell, A. J., Pennington, B., Pericleous, L., Rowen, D., Lebmeier, M., & Lee, D. (2014) · Health and Quality of Life Outcomes · doi:10.1186/s12955-014-0140-1 · Cited by 48 · see citing works
A systematic review of health economic models and utility estimation methods in schizophrenia
Németh, B., Fasseeh, A. N., Molnár, A., Bitter, I., Horváth, M., Kóczián, K., Götze, Á., & Nagy, B. (2018) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1430571 · Cited by 48 · see citing works
QLiS – development of a schizophrenia-specific quality-of-life scale
Franz, M., Fritz, M., Gallhofer, B., & Meyer, T. (2012) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-10-61 · Cited by 44 · see citing works
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Ruíz, A., Pérez-Costillas, L., Montesinos, A., Alcalde, J., Oyagüez, I., & Casado, M. A. (2012) · Health Economics Review · doi:10.1186/2191-1991-2-8 · Cited by 44 · see citing works
Osborne, R. H., Dalton, A., Hertel, J., Schrover, R., & Smith, D. (2012) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-10-35 · Cited by 39 · see citing works
Boye, K. S., Matza, L. S., Feeny, D. H., Johnston, J. A., Bowman, L., & Jordan, J. B. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2014.912562 · Cited by 39 · see citing works
Kane, J. M., Durgam, S., Satlin, A., Vanover, K. E., Chen, R., Davis, R. E., & Mates, S. L. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000371 · Cited by 38 · see citing works
Mehnert, A., Nicholl, D., Pudas, H., Martin, M., & McGuire, A. J. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.681531 · Cited by 34 · see citing works
Ho, A. (2023) · doi:10.1093/med/9780197556269.001.0001 · Cited by 33 · see citing works
Correll, C. U., Vanover, K. E., Davis, R. E., Chen, R., Satlin, A., & Mates, S. L. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.006 · Cited by 33 · see citing works
Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
Zeidler, J., Mahlich, J., Greiner, W., & Heres, S. (2013) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0050-0 · Cited by 32 · see citing works
Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
Park, T., & Kuntz, K. M. (2014) · Value in Health · doi:10.1016/j.jval.2014.02.008 · Cited by 28 · see citing works
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden
Einarson, T. R., Vicente, C., Zilbershtein, R., Piwko, C., Bø, C. N., Pudas, H., Jensen, R., & Hemels, M. E. H. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2013.852243 · Cited by 28 · see citing works
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
Einarson, T. R., Geitona, M., Chaidemenos, A., Karpouza, V., Mougiakos, T., Paterakis, P., Ploumpidis, D., Potamitis-Komis, D., Zilbershtein, R., Vicente, C., et al. (2012) · Annals of General Psychiatry · doi:10.1186/1744-859x-11-18 · Cited by 27 · see citing works
Doctor, J. N., Zoellner, L. A., & Feeny, N. C. (2011) · Psychiatric Services · doi:10.1176/ps.62.3.pss6203_0272 · Cited by 26 · see citing works
Zomer, E., Osborn, D., Nazareth, I., Blackburn, R. M., Burton, A., Hardoon, S. L., Holt, R. I. G., King, M., Marston, L., Stephen Morris, A., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-018181 · Cited by 22 · see citing works
Einarson, T. R., Pudas, H., Goswami, P., Impe, K. V., & Bereza, B. G. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1100115 · Cited by 24 · see citing works
Murray, R. M., Correll, C. U., Reynolds, G. P., & Taylor, D. M. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317693200 · Cited by 23 · see citing works
Debaveye, S., Soete, W. D., Meester, S. D., Vandijck, D. M., Heirman, B., Kavanagh, S., & Dewulf, J. P. (2015) · Environmental Research · doi:10.1016/j.envres.2015.10.027 · Cited by 22 · see citing works
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal
Einarson, T. R., Maia-Lopes, S., Goswami, P., Bereza, B. G., & Impe, K. V. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1184156 · Cited by 22 · see citing works
Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia
Buoli, M., Kahn, R. S., Serati, M., Altamura, A. C., & Cahn, W. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2542 · Cited by 22 · see citing works
Debaveye, S., Smedt, D. D., Heirman, B., Kavanagh, S., & Dewulf, J. P. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4247-2 · Cited by 22 · see citing works
Elicitation of Informed General Population Health State Utility Values: A Review of the Literature
McTaggart-Cowan, H. M. (2011) · Value in Health · doi:10.1016/j.jval.2011.05.046 · Cited by 22 · see citing works
Amaresha, A. C., Kalmady, S. V., Joseph, B., Agarwal, S. M., Narayanaswamy, J. C., Venkatasubramanian, G., Muralidhar, D., & Subbakrishna, D. K. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.11.030 · Cited by 21 · see citing works
Cost-Effectiveness of School-Based Prevention of Cannabis Use
Deogan, C., Zarabi, N., Stenström, N., Högberg, P., Skärstrand, E., Manrique-Garcia, E., Neovius, K., & Månsdotter, A. (2015) · Applied Health Economics and Health Policy · doi:10.1007/s40258-015-0175-4 · Cited by 20 · see citing works
A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States
Mavranezouli, I. (2010) · PharmacoEconomics · doi:10.2165/11537300-000000000-00000 · Cited by 20 · see citing works
Cullen, B., Rodriguez, K. M., Eaton, W. W., Mojtabai, R., Mach, T. V., & Ybarra, M. L. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113346 · Cited by 19 · see citing works
Health State Utility Values in Schizophrenia: A Systematic Review and Meta-Analysis
Aceituno, D., Pennington, M., Iruretagoyena, B., Prina, M. A., & McCrone, P. (2020) · Value in Health · doi:10.1016/j.jval.2020.05.014 · Cited by 17 · see citing works
Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.
(2018) · Europe PMC (PubMed Central) · Cited by 17 · see citing works
Einarson, T. R., Vicente, C., Zilbershtein, R., Piwko, C., Bø, C. N., Pudas, H., & Hemels, M. E. H. (2012) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2012.00670.x · Cited by 17 · see citing works
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Rajagopalan, K., Trueman, D., Crowe, L., Squirrell, D., & Loebel, A. D. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0405-0 · Cited by 17 · see citing works
Nuhoho, S., Saad, A., Saumell, G., Ribes, D., & Khoury, A. C. E. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1417246 · Cited by 16 · see citing works
Einarson, T. R., Pudas, H., Zilbershtein, R., Jensen, R., Vicente, C., Piwko, C., & Hemels, M. E. H. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.823869 · Cited by 16 · see citing works
Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes
Sawyer, L., Azorin, J., Chang, S., Rinciog, C., Guiraud-Diawara, A., Marre, C., & Hansen, K. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.914030 · Cited by 15 · see citing works
Jin, H., McCrone, P., & MacCabe, J. H. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-019-01108-4 · Cited by 15 · see citing works
Amaresha, A. C., Venkatasubramanian, G., & Muralidhar, D. (2019) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_318_19 · Cited by 15 · see citing works
Zhou, J., Millier, A., François, C., Aballéa, S., & Toumi, M. (2019) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2019.1648973 · Cited by 15 · see citing works
Jørgensen, T. R., Emborg, C., Dahlen, K., Bøgelund, M., & Carlborg, A. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0930-6 · Cited by 14 · see citing works
Utility decrements associated with side effects in schizophrenia
Millier, A., Amri, I., Boyer, L., Auquier, P., & Toumi, M. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.964405 · Cited by 14 · see citing works
Graham, C. N., Mauskopf, J., Lawson, A. H., Ascher‐Svanum, H., & Bruhn, D. F. (2011) · Value in Health · doi:10.1016/j.jval.2011.08.1741 · Cited by 14 · see citing works
Osborn, D., Burton, A., Walters, K. R., Atkins, L., Barnes, T. R. E., Blackburn, R. M., Craig, T., Gilbert, H. M., Gray, B. V., Hardoon, S. L., et al. (2019) · Programme Grants for Applied Research · doi:10.3310/pgfar07020 · Cited by 13 · see citing works
Assessing the needs of siblings of persons with schizophrenia: A qualitative study from India
Amaresha, A. C., Joseph, B., Agarwal, S. M., Narayanaswamy, J. C., Venkatasubramanian, G., Muralidhar, D., & Subbakrishna, D. K. (2015) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2015.07.011 · Cited by 14 · see citing works
Caresano, C., Sciascio, G. D., Fagiolini, A. M., Maina, G., Perugi, G., Ripellino, C., & Vampini, C. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0139-3 · Cited by 13 · see citing works
Einarson, T. R., Zilbershtein, R., Skoupá, J., Veselá, Š., Garg, M., & Hemels, M. E. H. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.820193 · Cited by 13 · see citing works
von Scheele, B., Mauskopf, J., Brodtkorb, T., Ainsworth, C., Berardo, C. G., & Patel, A. K. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2014.891443 · Cited by 13 · see citing works
Rekhi, G., Tay, J., & Lee, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211055812 · Cited by 12 · see citing works
Estimation of a Multiattribute Utility Function for the Spanish Version of the TooL Questionnaire
Montejo, A. L., Correas-Lauffer, J., Mauriño, J., Villa, G., Rebollo, P., Díez, T., & Cordero, L. (2011) · Value in Health · doi:10.1016/j.jval.2010.11.016 · Cited by 12 · see citing works
King, D., Knapp, M. R. J., Thomas, P., Razzouk, D., Loze, J.-Y., Kan, H., & van Baardewijk, M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.542745 · Cited by 12 · see citing works
Mavranezouli, I., & Lokkerbol, J. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0473-1 · Cited by 12 · see citing works
Estimating utility value for female genital mutilation
Alinia, C., Piroozi, B., Jahanbin, F., Safari, H., Bolbanabad, A. M., Karyani, A. K., Moradi, G., Farhadifar, F., & Ebrahimi, M. (2020) · BMC Public Health · doi:10.1186/s12889-020-08947-4 · Cited by 11 · see citing works
Awad, G. A., Hassan, M., Loebel, A. D., Hsu, J., Pikalov, A., & Rajagopalan, K. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-53 · Cited by 11 · see citing works
Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia
Jukić, V., Jakovljević, M., Filipčić, I., Herceg, M., Silić, A., Tomljanović, T., Zilbershtein, R., Jensen, R., Hemels, M. E. H., & Einarson, T. R. (2013) · Value in Health Regional Issues · doi:10.1016/j.vhri.2013.06.008 · Cited by 12 · see citing works
Wang, L., Shi, F., Guan, X., Xu, H., Liu, J., & Li, H. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.689123 · Cited by 10 · see citing works
Ybarra, M. L., Rodriguez, K. M., Madison, H., Mojtabai, R., & Cullen, B. (2019) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001037 · Cited by 9 · see citing works
Uttley, L., Kearns, B., Ren, S., & Stevenson, M. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0091-0 · Cited by 9 · see citing works
Montejo, A. L., Correas-Lauffer, J., Cuervo, J., Rebollo, P., Cordero, L., Díez, T., & Mauriño, J. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-6 · Cited by 9 · see citing works
Duarte, C., Fakra, É., van Gils, C., & Guillon, P. (2019) · L Encéphale · doi:10.1016/j.encep.2019.03.001 · Cited by 8 · see citing works
Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia
Rejón-Parrilla, J. C., Nuijten, M. J. C., Redekop, K., & Gaultney, J. G. (2014) · Health Policy and Technology · doi:10.1016/j.hlpt.2014.08.004 · Cited by 8 · see citing works
Flood, C., Barlow, S. H., Simpson, A., Burls, A., Price, A. I., Cartwright, M., & Brini, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205223 · Cited by 8 · see citing works
Haloperidol Versus Second-Generation Antipsychotics in the Long-Term Treatment of Schizophrenia
Altamura, A. C., Buoli, M., & Mauri, M. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822c989a · Cited by 7 · see citing works
Physical activity and severe mental illness
Fibbins, H., Lederman, O., & Rosenbaum, S. (2021) · Society for Transparency, Openness, and Replication in Kinesiology eBooks · doi:10.51224/b1017 · Cited by 7 · see citing works
Ybarra, M. L., Rodriguez, K. M., Fehmie, D. A., Mojtabai, R., & Cullen, B. (2021) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001421 · Cited by 7 · see citing works
Lee, E. H. M., Hui, C. L. M., Lin, J., Ching, E. Y. N., Chang, W. C., Chan, S. K. W., & Chen, E. Y. H. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12246 · Cited by 7 · see citing works
Quality of Life in Psychosis: Prevalence and Associated Factors in a Nigerian Clinical Population
Lasebikan, V. O., & Owoaje, E. (2015) · Community Mental Health Journal · doi:10.1007/s10597-015-9842-z · Cited by 9 · see citing works
Furiak, N. M., Gahn, J. C., Klein, R. W., Camper, S. B., & Summers, K. H. (2012) · Annals of General Psychiatry · doi:10.1186/1744-859x-11-29 · Cited by 7 · see citing works
Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals
Debaveye, S., Smedt, D. D., Heirman, B., Kavanagh, S., & Dewulf, J. P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229235 · Cited by 7 · see citing works
Evaluation of health promotion programmes in severe mental illness: theory and practice
van Hasselt, F. M., Krabbe, P. F. M., Postma, M. J., & LOONEN, A. J. M. (2014) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1456 · Cited by 6 · see citing works
Wang, C., Oughourlian, T. C., Tishler, T. A., Anwar, F., Raymond, C., Pham, A. D., Perschon, A., Villablanca, J. P., Ventura, J., Subotnik, K. L., et al. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.04.001 · Cited by 6 · see citing works
Papageorgiou, K., Vermeulen, K. M., Leijten, F., Buskens, E., Ranchor, A. V., & Schroevers, M. J. (2014) · Health Expectations · doi:10.1111/hex.12303 · Cited by 6 · see citing works
Quintero, J., Oyagüez, I., González, B., Cuervo-Arango, I., García, I., & Casado, M. Á. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0393-z · Cited by 5 · see citing works
Yi, Z., Men, P., Qu, S., Li, C., Yu, X., & Zhai, S. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1752670 · Cited by 4 · see citing works
Acknowledging Patient Heterogeneity in Economic Evaluations in Schizophrenia: A Systematic Review
Shields, G., Camacho, E. M., Farragher, T. M., Clarkson, P., Verma, A., & Davies, L. M. (2021) · Value in Health · doi:10.1016/j.jval.2021.07.001 · Cited by 4 · see citing works
Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
Liu, J., Cao, L., & Wu, J. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.987408 · Cited by 4 · see citing works
Hemels, M. E. H., Einarson, T. R., Zilbershtein, R., Schubert, A., Skrzekowska-Baran, I., & Impe, K. V. (2013) · Value in Health · doi:10.1016/j.jval.2013.08.1406 · Cited by 4 · see citing works
Health utility estimation in children and adolescents: a review of health technology assessments
Bégo-Le-Bagousse, G., Jia, X., Wolowacz, S. E., Eckert, L., Tavi, J., & Hudson, R. D. A. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1762553 · Cited by 4 · see citing works
Xiao, L., Gao, Y., Zhang, L., Chen, P., Sun, X., & Tang, S. (2016) · Quality of Life Research · doi:10.1007/s11136-016-1319-1 · Cited by 3 · see citing works
Dopamine docking studies of biologically active metabolites from Curcuma longa L.
Bernardi, D. M., Marchi, J. P., Araújo, C. D. S. A., do Nascimento, V. R., Lima, D. D. S., Wietzikoski, S., Ferro, M. M., Miyoshi, E., Lívero, F. A. D. R., Seixas, F. A. V., et al. (2021) · Research Society and Development · doi:10.33448/rsd-v10i7.16992 · Cited by 4 · see citing works
van Hasselt, F. M. (2013) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 3 · see citing works
Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
Luo, R., Lu, H., & Li, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1238028 · Cited by 2 · see citing works
Cost/effectiveness of aripiprazole vs. olanzapine in the long-term treatment of schizophrenia
Dutina, A., Stašević-Karličić, I., Pandrc, N., Prokić, A., & Јаnkovic, S. (2019) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh181012065d · Cited by 2 · see citing works
Furiak, N. M., Duhig, A. M., Myers, J. A., Pitts, A., Hass, S., & Klein, R. W. (2014) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2013.11.001 · Cited by 2 · see citing works
Translating genomic research into care for people with schizophrenia in China
Chan, R. C. K., Austin, J., Pearson, V. J., Gong, Q., & Honer, W. G. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.008 · Cited by 2 · see citing works
Ravasio, R., Nicolò, G., & Vaggi, M. (2014) · Global & Regional Health Technology Assessment · doi:10.5301/grhta.5000186 · Cited by 2 · see citing works
Paranoid Thinking and Wellbeing. The Role of Doubt in Pharmacological and Metacognitive Therapies
Aguerri, L. A., Beato‐Fernández, L., Stavraki, M., Rodríguez‐Cano, T., Bajo, M., & Díaz, D. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.02099 · Cited by 3 · see citing works
Outcomes Measurement for Economic Evaluation
Razzouk, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-55266-8_3 · Cited by 2 · see citing works
Ho, A. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197556269.003.0005 · Cited by 1 · see citing works
Hemels, M. E. H., Zilbershtein, R., Schubert, A., Skrzekowska-Baran, I., & Impe, K. V. (2013) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2013.4.6 · Cited by 1 · see citing works
Rajagopalan, K., Trueman, D., Crowe, L., Patel, P., & Loebel, A. D. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.968 · Cited by 1 · see citing works
Ho, A. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197556269.003.0001 · Cited by 1 · see citing works
A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
Abdall-Razak, A., Macaulay, A., Tiefenbach, J., Borges, K., Mathema, S., & Zuberi, S. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02343 · Cited by 1 · see citing works
Zhand, N., Desai, N., Park, A., & Dick, M. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01426-3 · Cited by 1 · see citing works
Mavranezouli, I. (2014) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
- Authors
- Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D., & Mukherjee, J.
- Affiliations
- University of Manchester (GB)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Corresponding author
- Wild, Diane
- Venue
- Health and Quality of Life Outcomes
- Published
- 2008-11-28
- Volume
- 6
- Issue
- 1
- Pages
- 105-105
- ISSN
- 1477-7525 (ISSN-L)
- PMC
- PMC2613374
- OpenAlex
- W2168395707
- Cited by
- 122
- References
- 21
- Citations by year
- 2026: 4 · 2025: 1 · 2023: 14 · 2022: 3 · 2021: 8 · 2020: 9 · 2019: 11 · 2018: 5 · 2017: 4 · 2016: 8 · 2015: 8 · 2014: 16 · 2013: 9 · 2012: 7
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Health and Quality of Life Outcomes (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- University of Manchester
- Deakin University
- University of Toronto
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Environmental Valuation
- Keywords
- schizophrenia, quality of life, antipsychotic adverse effects, hyperprolactinemia, antipsychotic-induced diabetes, weight gain, relapse, health utility, time trade-off, health state descriptions
- MeSH terms
- Adolescent, Adult, Aged, England, Female, Humans, Interviews as Topic, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Schizophrenia, Antipsychotic Agents, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
